نتائج البحث - "Amal Arahmani"

1

Abstract OT1-04-01: AMEERA-6: Phase 3 Study of Adjuvant Amcenestrant Versus Tamoxifen for Patients With Hormone Receptor-Positive Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

المصدر: Cancer Research. 83:OT1-04

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b26ea28b4eddfe29aadba27ed848cdc3
https://doi.org/10.1158/1538-7445.sabcs22-ot1-04-01

2

Table S1, Table S2; Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31c8f614a23932f5aed19174e8e3699a
https://doi.org/10.1158/1078-0432.22474223.v1

3

Data from Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32cf04ddf0d07a6cb6022d16c020f28e
https://doi.org/10.1158/1078-0432.c.6528728.v1

4

Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)

المصدر: Cancer Research. 82:P4-10

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7f2437005b23fbc8bc68537113e1f263
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-01

5

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

المصدر: New England Journal of Medicine, 384(25), 2394-2405. MASSACHUSETTS MEDICAL SOC
The New England journal of medicine, vol 384, iss 25

مصطلحات موضوعية: medicine.medical_treatment, Synthetic lethality, Medical and Health Sciences, Poly (ADP-Ribose) Polymerase Inhibitor, Piperazines, chemistry.chemical_compound, ErbB-2, Adjuvant, Mastectomy, Polymerase, Cancer, biology, General Medicine, Middle Aged, 6.1 Pharmaceuticals, Female, Receptor, Adult, Clinical Trials and Supportive Activities, Breast Neoplasms, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Disease-Free Survival, Olaparib, Breast cancer, Double-Blind Method, Clinical Research, General & Internal Medicine, Breast Cancer, medicine, Humans, Chemotherapy, Germ-Line Mutation, business.industry, Evaluation of treatments and therapeutic interventions, BRCA1, medicine.disease, BRCA2, Good Health and Well Being, Genes, chemistry, biology.protein, Cancer research, Phthalazines, Digestive Diseases, Homologous recombination, business, OlympiA Clinical Trial Steering Committee and Investigators

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e52f9a2de90257dee369f76dcfb6c2
https://doi.org/10.1056/nejmoa2105215

Find this article in full text from ProQuest

6

DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade

المؤلفون: Veronique Debien, Virginie ADAM, Rafael Caparica, Debora Fumagalli, Chloé Velghe, Julie Gaye, Vanessa Correia De Nobrega, Amal Arahmani, Gabriele Zoppoli, Martine J. Piccart-Gebhart

المصدر: Journal of Clinical Oncology. 40:TPS621-TPS621

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c8086e5418888a60c713c10fa937dcdb
https://doi.org/10.1200/jco.2022.40.16_suppl.tps621

7

Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)

المصدر: Journal of Clinical Oncology. 40:TPS607-TPS607

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e4349224ec649f85fd37199d34dd7a3a
https://doi.org/10.1200/jco.2022.40.16_suppl.tps607

8

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

المؤلفون: Christian Jackisch, Amal Arahmani, Jennifer A. Petersen, Emma Clark, José Baselga, Martine Piccart, Elizabeth S. Frank, Giuseppe Viale, Amir Sonnenblick, Marion Procter, Eleonora Restuccia, Linda Reaby, José Bines, Damien Parlier, Debora Fumagalli, Richard D. Gelber, Claire Barton

المصدر: Br J Cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b693638ee9772c365ab475e3e80af63
https://pubmed.ncbi.nlm.nih.gov/33828257

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

9

Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer

المؤلفون: R. D. Gelber, Emma Clark, Thomas M. Suter, Amal Arahmani, E. de Azambuja, Dimitrios Zardavas, J. Baselga, Marion Procter, Eleonora Restuccia, José Bines, Jennifer Eng-Wong, M.J. Piccart, V Van Dooren, G. Viale, G. von Minckwitz

المصدر: Cancer Research. 78:P1-13

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4ac8e83679c8e498f4eb2f15b10f72de
https://doi.org/10.1158/1538-7445.sabcs17-p1-13-07

10

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer

المصدر: Journal of Clinical Oncology. 39:LBA1-LBA1

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, HER2 negative, Placebo-controlled study, Synthetic lethality, Germline, Olaparib, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Homologous recombination, business, Adjuvant, Early breast cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::467a7a2b8f8deb94777ab81b3c2e75c8
https://doi.org/10.1200/jco.2021.39.15_suppl.lba1

تنقيح النتائج